Clinical trials: Movement Abnormalities
Idiopathic Parkinson's Disease, Drug Induced Dyskinesia
Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease
The study will involve an eighteen-week, double-blind, placebo-controlled parallel designed comparison between add-on topiramate and add-on placebo to stable treatment with amatadine in the treatment of Parkinson's disease (PD)…
- Trial name
- TOP-DYSK (NCT01789047)
- Testing
- Topiramate, Amantadine
- Where
- 5 sites in United States
- Volunteers
- 42 people
- Sponsor
- Rush University Medical Center
Dementia With Lewy Bodies (DLB)
A Double-blind Study of E2020 (Donepezil Hydrochloride) in Patients With Dementia With Lewy Bodies (DLB) (Study E2020-J081-431)
The purpose of this study is to evaluate the efficacy and safety of E2020 in patients with Dementia with Lewy Bodies (DLB).
- Trial name
- NCT00543855
- Testing
- 3 mg Donepezil hydrochloride, 5 mg Donepezil hydrochloride, 10 mg Donepezil hydrochloride
- Where
- 43 sites in Japan
- Volunteers
- 167 people
- Sponsor
- Eisai Co., Ltd.
Essential Tremor
A Clinical Trial of PRAX-944 in Participants With Essential Tremor
This is a 2-part clinical trial to evaluate the efficacy, safety, and tolerability of 40 and 120 mg oral PRAX-944 compared to placebo in the treatment of adults with essential tremor.
- Trial name
- NCT05021978
- Testing
- Part A: 20 and 40 mg PRAX-944, Part B: 120 mg PRAX-944
- Where
- 9 sites in United States, Australia and 1 more
- Volunteers
- 24 people
- Sponsor
- Praxis Precision Medicines
Early Manifest Huntington Disease
A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070/Branaplam in Early Manifest Huntington's Disease
This is the first study of branaplam in adults with Huntington's Disease (HD) to determine the correct dose required to lower mutant huntingtin protein (mHTT) levels in the cerebrospinal fluid (CSF) to a degree expected to be…
- Trial name
- VIBRANT-HD (NCT05111249)
- Testing
- Branaplam
- Where
- 12 sites in Canada, France and 3 more
- Volunteers
- 26 people
- Sponsor
- Novartis Pharmaceuticals
Parkinson's
Cognitive Dysfunction In Parkinson's
We hypothesize that reductions in gamma activity are a key mechanism underlying cognitive dysfunction in PD and that interventions to increase gamma activity will improve cognition.
- Trial name
- KL2 (NCT02468804)
- Testing
- rTMS
- Where
- United States
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Ataxia, Cerebellar, Cerebellar Ataxia
Rehabilitative Trial With Cerebello-Spinal tDCS in Neurodegenerative Ataxia
Neurodegenerative cerebellar ataxias represent a group of disabling disorders for which we currently lack effective therapies. Cerebellar transcranial direct current stimulation (tDCS) is a non-invasive technique, which has been…
- Conditions
- Ataxia, Cerebellar, Cerebellar Ataxia, Spinocerebellar Ataxias, Ataxia, Spinocerebellar
- Trial name
- CStDCSAtaxia (NCT03120013)
- Testing
- Anodal cerebellar and cathodal spinal tDCS
- Where
- Italy
- Volunteers
- 21 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Parkinson Disease
Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations
The purpose of this study is to evaluate the efficacy, safety and tolerability of PF-06649751 in Parkinson's disease patients who experience motor-fluctuations.
- Trial name
- NCT02687542
- Testing
- PF-06649751 low dose (1 mg QD), PF-06649751 middle dose 1 (3 mg QD), PF-06649751 middle dose 2 (7 mg QD)
- Where
- 57 sites in United States, Canada and 4 more
- Volunteers
- 108 people
- Sponsor
- Pfizer
Parkinson's Disease
An RCT of a Telemedicine Intervention for Hypokinetic Dysarthria in PD
Nearly 90% of people with Parkinson's disease have speech and voice disorders that negatively impact their ability to communicate effectively in daily life.
- Trial name
- NCT04617496
- Testing
- Combined speech and exercise intervention, Health education
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- VA Office of Research and Development
Parkinson Disease
Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease (PD) Participants With Motor Fluctuations
The purpose of this study is to evaluate the long-term safety and clinical utility of IPX203 in the treatment of participants with advanced Parkinson's disease (PD) who have motor fluctuations.
- Trial name
- NCT03877510
- Testing
- IPX203
- Where
- 98 sites in United States, Czechia and 6 more
- Volunteers
- 419 people
- Sponsor
- Impax Laboratories, LLC
Parkinson Disease
Nabilone for Non-motor Symptoms in Parkinson's Disease
This is an open-label extension study for participants of the randomized placebo-controlled, double-blind, parallel-group, enriched enrolment randomized withdrawal NMS-Nab Study, assessing the long-term safety and efficacy of…
- Trial name
- NMS-Nab2 (NCT03773796)
- Testing
- Nabilone 0.25 mg
- Where
- Austria
- Volunteers
- 22 people
- Sponsor
- Medical University Innsbruck
Parkinson's Disease
Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease
Levodopa is the main drug treatment for Parkinson's disease. Levodopa can cause unwanted and uncontrolled movements called dyskinesias. A drug called amantadine can reduce these movements.
- Trial name
- NCT00794313
- Testing
- Amantadine 300 mg, Topiramate, Sugar Pill
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Oregon Health and Science University
Parkinson's Disease
Telephone-linked Home-based Exercise Training in PD
This project is investigating whether a home-based exercise program will reduce depression in patients with Parkinson's disease.
- Trial name
- NCT02898740
- Testing
- Structural exercise, Health education
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- VA Office of Research and Development
Parkinson Disease
Robotic Walking Device to Improve Mobility in Parkinson's Disease
This Phase II randomized controlled trial proposes to examine the impact of long-term use of a novel light-weight and wearable assistive robotic device, called the Honda Walking Assist (HWA) device, to improve mobility in the…
- Trial name
- NCT03751371
- Testing
- Training with HWA device, Usual Care
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Ohio State University
Parkinson Disease
Walking and mHealth to Increase Participation in Parkinson Disease
Identifying effective ways to improve function, slow decline and reduce disability is a high priority for people living with Parkinson disease and other chronic conditions.
- Trial name
- WHIPPD (NCT03517371)
- Testing
- mHealth delivered exercise program, Exercise only
- Where
- 2 sites in United States
- Volunteers
- 140 people
- Sponsor
- Boston University Charles River Campus
Parkinson Disease
Vibration Impact on Parkinson's Tremor
The primary purpose of this study is to test the safety, tolerability and efficacy of vibration (delivered by an experimental device called RMBand that is worn on the subject's arm) on parkinsonian tremor.
- Trial name
- NCT03799614
- Testing
- RMBand lower dose, RMBand higher dose
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Virginia Commonwealth University
Parkinson Disease
Effect of BIA 9-1067 on Rasagiline Pharmacokinetics
The purpose of this study is to investigate the effect of BIA 9-1067 on rasagiline pharmacokinetics in healthy subjects.
- Trial name
- NCT01532128
- Testing
- rasagiline, BIA 9-1067
- Where
- France
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Tardive Dyskinesia
Addressing Involuntary Movements in Tardive Dyskinesia
The purpose of this study is to determine whether fixed-doses of an investigational drug, SD-809 (deutetrabenazine), will reduce the severity of abnormal involuntary movements of tardive dyskinesia.
- Trial name
- AIM-TD (NCT02291861)
- Testing
- SD-809
- Where
- 106 sites in United States, Czechia and 4 more
- Volunteers
- 298 people
- Sponsor
- Auspex Pharmaceuticals, Inc.
Parkinson Disease
A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (P04938)
When a patient with Parkinson's disease (PD) is initially treated with L-dopa or dopamine agonists, the symptoms of PD improve or disappear.
- Trial name
- NCT01155466
- Testing
- Preladenant 2 mg tablet, Preladenant 5 mg tablet, Preladenant 10 mg tablet
- Volunteers
- 778 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson Disease, Multiple System Atrophy
Treatment of Parkinson Disease and Multiple System Atrophy Using Intranasal Insulin.
Parkinson disease (PD) and multiple system atrophy (MSA) are progressive neurodegenerative disorders characterized by abnormal accumulation of α-synuclein.
- Trial name
- NCT02064166
- Testing
- Intranasal Insulin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Peter Novak
Parkinson's Disease
A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's Disease
Parkinson's disease (PD) is a common neurodegenerative disease affecting movement. Although drug treatments for PD are available they only treat the symptoms of the disease, fail to halt neuronal loss, and are associated with…
- Trial name
- DeferipronPD (NCT01539837)
- Testing
- Deferiprone 20mg, Deferiprone 30mg
- Where
- United Kingdom
- Volunteers
- 22 people
- Sponsor
- Imperial College London